Your browser doesn't support javascript.
loading
Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma.
Gu, Xiaoying; Zhang, Su; Yang, Xuejiao; Guan, Tao; Hou, Zhenyu; Cao, Manqing; Li, Huikai; Zhang, Ti.
Afiliación
  • Gu X; Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Zhang S; Department of Gynecologic Oncology, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Yang X; Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Guan T; Present Address: Department of Anesthesiology, The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, 445000, EnshiHubei, China.
  • Hou Z; Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Cao M; Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Li H; Department of Breast Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
  • Zhang T; Department of Hepatobiliary Surgery, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China. tjchlhk@126.com.
BMC Gastroenterol ; 22(1): 441, 2022 Oct 31.
Article en En | MEDLINE | ID: mdl-36316630
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas / Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: BMC Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: China